Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,626

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

3,626 results for “vitamins”

Learn how ShareScore rates datasets ↗
zenodo20/100

Patient-derived metastatic melanoma cells treated with vitamin D and anticancer drugs

<ol> <li><strong>Immunofluorescence staining</strong></li> </ol> <p>For immunofluorescence analyses cells isolated from malignant melanoma tumour were seeded in 8-well chamber slides, fixed with 4% paraformaldehyde (PFA) for 10 min and permeabilized for 5 min in 0.2% Triton X100 in PBS. Slides were washed three times with PBS and incubated with 1% BSA for 30 min at RT. Following blocking appropriate primary antibody in 0.1% BSA (Thermo Fisher Scientific: PMEL (HMB45) MA5-13232, 1:40; Melan-A MA5-15237, 1:100 or MA5-32217, 1:200; Cell Signaling Technology: FAP Cat. No. 66562, 1:100) was applied and the slides were incubated in humidified chamber at 4 &deg;C overnight. Subsequently slides were washed three times in PBS, and incubated with secondary antibody (ThermoFisher Scientific either Alexa Fluor&reg; 488 conjugate goat anti rabbit IgG A11008 or Alexa Fluor&reg; 594 conjugate donkey anti mouse IgG A21203) solution in PBS for 1 h at RT in dark. Following three washing steps in PBS the slides were counterstained with 4&prime;,6&prime;-diamidinio-2-phenylindole (DAPI). Images were collected with a fluorescence microscope Olympus cell Vivo IX 83. For a-SMA (alpha-smooth muscle actin) immunofluorescence analyses the procedure of staining with Melan A was proceeded to the appropriate secondary antibodies as described above. Subsequently antibody against a-SMA PE‑conjugated (R&amp;D Systems: IC1420P, 1:50) was applied to the specimen for an additional 30 min in humidified chamber at 4 &deg;C. Following three washing steps in PBS the slides were counterstained with DAPI. Images were collected with a fluorescence microscope Olympus cell Vivo IX 83 as Z‑stacks.</p> <ol> <li><strong>SRB viability assay</strong></li> </ol> <p>The viability of cells isolated from metastatic malignant melanoma tissues treated with 1,25(OH)<sub>2</sub>D<sub>3</sub>, vemurafenib or both was assessed with sulforhodamine B (SRB). The cells were seeded in 96-well plates at 2,000 of cells per well density and left overnight. Subsequently the cells were treated simultaneously with serial dilutions of vemurafenib (3,15-200 nM) and 1,25(OH)<sub>2</sub>D<sub>3</sub> at 100 nM or 1 &micro;M concentration for 72 h. Cells were fixed with 10% trichloroacetic acid for 1 h at 4&deg;C, washed with distilled water and stained for 15 min with 0.4% SRB solution (Sigma&ndash;Aldrich; Merck KGaA) in 1 % acetic acid. SRB dye was solubilized using a solution of 10 mM buffered Tris Base (pH 10.5) and absorbance measured at 570 nm using an Epoch spectrophotometer (BioTek, Winooski, USA). The relative IC50 value was calculated as the mid‑point between no inhibition and the maximum observed decrease in proliferation (n=6).</p> <ol> <li><strong>Proliferation rate assay</strong></li> </ol> <p>Proliferation rate analysis of the cells isolated from malignant melanoma tissues treated with 1,25(OH)<sub>2</sub>D<sub>3</sub> at 100 nM concentration and cediranib at 1000 nM concentration was carried out as a live imaging with Olympus cell Vivo IX 83, equipped with CO<sub>2</sub> incubator and enables for stable cell cultivation at 37&deg;C, controlled humidity and 5% CO<sub>2</sub> during the whole 72 h experiment. Results were calculated with the Olympus cell Vivo IX 83 software with use of TruAI technology, normalized with 1.0 at the beginning of the experiment (n = 4).</p> <ol> <li><strong>Wound closure rate</strong></li> </ol> <p>The experiment was carried out as a live imaging with Olympus cell Vivo IX 83 and cell migration process was observed during 72 h incubation. The cells isolated from malignant melanoma tissues were seeded on a 8-well chamber slide (1.0 &times; 10<sup>5</sup> cells per well). A mechanical wound was created by scraping the confluent monolayer of cells with a 200 &micro;L pipette tip. Cediranib at 1000 nM concentration was added to the cells pretreated with 1,25(OH)<sub>2</sub>D<sub>3</sub> at 100 nM concentration for 24 h. The cell free area was calculated as a percentage closure relative to original size [(wound area in mm<sup>2</sup>)*100/(original wound area in mm<sup>2</sup>)] with use of TruAI technology of the Olympus cellSens software (n = 4).</p> <ol> <li><strong>Mitochondrial membrane potential</strong></li> </ol> <p>Patients-derived cells were seeded on an 8-well chamber slide (2.0 &times; 10<sup>4</sup> cells per well). After 24 h, cells were stained with MitoTracker&trade; Red CM-H<sub>2</sub>Xros (Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 70 nM concentration for 20 min at 37&deg;C, and washed two times with PBS. Cells were pretreated with 1,25(OH)<sub>2</sub>D<sub>3</sub> at 100 nM concentration for 24h. Subsequently cediranib at 1000 nM concentration was added to the cells in a fresh medium and mitochondria were observed for additional 24 h. The experiment was carried out as a live imaging with Olympus cell Vivo IX 83. Results were calculated as an area fraction ROI (&ldquo;the mitochondria&rdquo;) normalized with 1.0 at the beginning of the experiment with the Olympus cell Vivo IX 83 software, (n = 3 - 4).</p> <ol> <li><strong>Measurement of melanoma bioenergetics</strong></li> </ol> <p>Patients-derived cells were seeded at a density of 20,000 cells per well in an Agilent Seahorse microplate and cultured at 37&deg;C in 5% CO<sub>2</sub> until reaching 80% confluency in 80 &mu;L culture medium per well. Subsequently cells were incubated for 24 h with vemurafenib at 200 nM concentration or cediranib at 1000 nM concentration with or without 1,25(OH)<sub>2</sub>D<sub>3</sub> at 100 nM concentration. Additionally, selected cells were also pretreated with 1,25(OH)<sub>2</sub>D<sub>3</sub> at 100 nM concentration for 24 h and then incubated with the chosen anticancer drug at appropriate concentration for 24h. The Cell Mito Stress Test was performed as described by Franczak M. et al. (Franczak, M.; Kutryb-Zajac, B.; El Hassouni, B.; Giovannetti, E.; Granchi, C.; Minutolo, F.; Smolenski, R.T.; Peters, G.J. The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells. <em>Nucleosides Nucleotides Nucleic Acids </em><strong>2022</strong>, 1-11, doi:10.1080/15257770.2022.2031215.). The medium was changed before analysis for the XFp assay medium with 10 mM glucose, 2 mM glutamine and 1 mM pyruvate (Agilent, US). During the assay 1.5 &mu;M oligomycin, 1 &mu;M carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) and 0.5 &mu;M rotenone with antimycin were added sequentially for the Cell Mito Stress Test. The XFp sensor cartridge, with compounds used in the test, was incubated at 37 &deg;C in the non-CO<sub>2</sub> incubator for 15 minutes before the assay and plate with cells for 45 minutes. Each analysis was performed by the Agilent Seahorse XFp Analyzer (Agilent, Santa Clara, CA, USA). The oxygen consumption rate (OCR) and the mitochondrial respiration parameters were calculated with the software provided with the Agilent Seahorse XFp Analyzer (n = 2-5).</p>

openother-pdApr 2023View details →
zenodo20/100

Fig. 5 in Discovery of a stable vitamin C glycoside in crab apples (Malus sylvestris)

Fig. 5. Synthetic route to AAGs 2 and 2a. I. Acetone, CH3COCl, overnight, room temp. (RT), II. PhCH2Br, K2CO3, DMSO, 50 ̊C, 3.5 h, III. NaOH(aq), TBAB, CHCl3, 50 ̊C, 1 h, IV. Conc. HCl, MeOH, 40 ̊C, 45 min, V. H /Pd–C, MeOH, RT, 3 h, VI. MeONa, MeOH, 20 min, RT, IRA 120 (H +), overall yield 17% (2) and 24% (2a).

opennotspecifiedMay 2020View details →
zenodo20/100

Fig. 3 in Vitamin E in legume nodules: Occurrence and antioxidant function

Fig. 3. Differential effects of water deficit stress on α-tocopherol content of leaves, roots and nodules of soybean, alfalfa and pea plants. α-Tocopherol content in leaves, roots and nodules of soybean, alfalfa and pea plants (from top to bottom). Data correspond to the mean ± SE of n = 5 individuals. Results of statistics are shown (two-way ANOVA, P &lt;0.05). An asterisk indicates significant differences between water-stressed and irrigated plants. Letters indicate significant differences over time in water-stressed plants (Tukey posthoc test P &lt;0.05). NS, not significant. DAW, days after water withdrawal in water-stressed plants.

opennotspecifiedApr 2020View details →
zenodo20/100

Fig. 1 in Vitamin E in legume nodules: Occurrence and antioxidant function

Fig. 1. Identification and quantification of tocochromanols in legume nodules. (A) HPLC chromatograms (left) and LC-MS/MS identification (right) of α-tocopherol in nodules of soybean, alfalfa and pea plants. Precursor and product ion m/z used for LC-MS/MS identification was 430/163.1) α-tocopherol, 2) β-tocopherol, 3) unknown, 4) unknown. (B) Quantification of tocochromanols in leaves, roots and nodules of three studied legumes (soybean, alfalfa and pea plants). Data represent the mean ± SE of n = 10. Although peaks 3 and 4 found in pea nodules co-eluted with α- and γ-tocotrienol, respectively, in the HPLC chromatogram, they could not be confirmed by LC-MS/MS. BHT, butylated hydroxytoluene.

opennotspecifiedApr 2020View details →
ClinicalTrials.gov20/100

Vitamin C With Steroids for Gastrointestinal GVHD

ClinicalTrials.gov study NCT07197749. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females

ClinicalTrials.gov study NCT01107808. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

Vitamin D and Immunity: Photosynthesis Versus Supplementation

ClinicalTrials.gov study NCT03609970. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

Vitamin B12 Pregnancy Supplementation

ClinicalTrials.gov study NCT03522428. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

Effect of Homocysteine-lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease

ClinicalTrials.gov study NCT00693589. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

Vitamin D and Disease Activity in Ulcerative Colitis

ClinicalTrials.gov study NCT02717897. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

Prevalence of Serum-Vitamin D Abnormalities, Periodontitis and Anaemia in Patients With Melasma

ClinicalTrials.gov study NCT03241381. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

The Effect of Body Weight on Vitamin D Metabolism

ClinicalTrials.gov study NCT02629198. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

Study on Effects of a Dairy Product Based on Polyphenols and Enriched With Vitamins B6, B9 and B12 on Some Cardiovascular Factor of Risk

ClinicalTrials.gov study NCT00706888. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

The Relationship Between Vitamin D, Fingernail Thickness and Bone Density

ClinicalTrials.gov study NCT00006196. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency

ClinicalTrials.gov study NCT03233295. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics

ClinicalTrials.gov study NCT04183257. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

Vitamin D Satus in Adults With Newly Diagnosed ITP

ClinicalTrials.gov study NCT07146555. IPD Sharing: YES. Countries: 0. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov20/100

Vitamin A Supplementation in Children With Moderate to Severe COVID-19

ClinicalTrials.gov study NCT04920760. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

High-dose Intravenous Vitamin C (HDIVC) as Adjuvant Therapy in Critical Patients With Positive COVID-19. A Pilot Randomized Controlled Dose-comparison Trial.

ClinicalTrials.gov study NCT05029037. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov20/100

Vitamin D3 Supplementation and Stress Fracture Occurrence in High-Risk Collegiate Athletes

ClinicalTrials.gov study NCT03395171. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.